|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ENOPH1 |
Gene summary for ENOPH1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ENOPH1 | Gene ID | 58478 |
| Gene name | enolase-phosphatase 1 | |
| Gene Alias | E1 | |
| Cytomap | 4q21.22 | |
| Gene Type | protein-coding | GO ID | GO:0000096 | UniProtAcc | D6RA00 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58478 | ENOPH1 | LZE4T | Human | Esophagus | ESCC | 7.06e-10 | 1.66e-01 | 0.0811 |
| 58478 | ENOPH1 | LZE7T | Human | Esophagus | ESCC | 1.22e-09 | 6.35e-01 | 0.0667 |
| 58478 | ENOPH1 | LZE24T | Human | Esophagus | ESCC | 1.02e-12 | 4.67e-01 | 0.0596 |
| 58478 | ENOPH1 | LZE21T | Human | Esophagus | ESCC | 6.16e-05 | 2.77e-01 | 0.0655 |
| 58478 | ENOPH1 | LZE6T | Human | Esophagus | ESCC | 1.32e-02 | 6.83e-02 | 0.0845 |
| 58478 | ENOPH1 | P2T-E | Human | Esophagus | ESCC | 1.85e-40 | 8.75e-01 | 0.1177 |
| 58478 | ENOPH1 | P4T-E | Human | Esophagus | ESCC | 1.46e-33 | 8.18e-01 | 0.1323 |
| 58478 | ENOPH1 | P5T-E | Human | Esophagus | ESCC | 2.18e-14 | 3.00e-01 | 0.1327 |
| 58478 | ENOPH1 | P8T-E | Human | Esophagus | ESCC | 3.61e-24 | 3.46e-01 | 0.0889 |
| 58478 | ENOPH1 | P9T-E | Human | Esophagus | ESCC | 3.64e-11 | 2.78e-01 | 0.1131 |
| 58478 | ENOPH1 | P10T-E | Human | Esophagus | ESCC | 1.79e-20 | 5.53e-01 | 0.116 |
| 58478 | ENOPH1 | P11T-E | Human | Esophagus | ESCC | 3.71e-16 | 7.60e-01 | 0.1426 |
| 58478 | ENOPH1 | P12T-E | Human | Esophagus | ESCC | 1.29e-29 | 7.13e-01 | 0.1122 |
| 58478 | ENOPH1 | P15T-E | Human | Esophagus | ESCC | 1.75e-36 | 7.96e-01 | 0.1149 |
| 58478 | ENOPH1 | P16T-E | Human | Esophagus | ESCC | 6.88e-48 | 8.86e-01 | 0.1153 |
| 58478 | ENOPH1 | P17T-E | Human | Esophagus | ESCC | 1.61e-06 | 5.63e-01 | 0.1278 |
| 58478 | ENOPH1 | P19T-E | Human | Esophagus | ESCC | 2.74e-09 | 6.39e-01 | 0.1662 |
| 58478 | ENOPH1 | P20T-E | Human | Esophagus | ESCC | 4.68e-19 | 3.71e-01 | 0.1124 |
| 58478 | ENOPH1 | P21T-E | Human | Esophagus | ESCC | 1.25e-29 | 7.09e-01 | 0.1617 |
| 58478 | ENOPH1 | P22T-E | Human | Esophagus | ESCC | 1.12e-24 | 3.72e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00090672 | Liver | HCC | aspartate family amino acid biosynthetic process | 19/7958 | 21/18723 | 6.44e-06 | 7.84e-05 | 19 |
| GO:00090861 | Liver | HCC | methionine biosynthetic process | 12/7958 | 12/18723 | 3.46e-05 | 3.45e-04 | 12 |
| GO:00090662 | Liver | HCC | aspartate family amino acid metabolic process | 34/7958 | 49/18723 | 1.28e-04 | 1.06e-03 | 34 |
| GO:00000971 | Liver | HCC | sulfur amino acid biosynthetic process | 15/7958 | 17/18723 | 1.31e-04 | 1.07e-03 | 15 |
| GO:00065551 | Liver | HCC | methionine metabolic process | 14/7958 | 16/18723 | 2.73e-04 | 1.98e-03 | 14 |
| GO:0043094 | Liver | HCC | cellular metabolic compound salvage | 20/7958 | 26/18723 | 3.82e-04 | 2.61e-03 | 20 |
| GO:0046500 | Liver | HCC | S-adenosylmethionine metabolic process | 13/7958 | 15/18723 | 5.67e-04 | 3.61e-03 | 13 |
| GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
| GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
| GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
| GO:00086524 | Oral cavity | OSCC | cellular amino acid biosynthetic process | 42/7305 | 76/18723 | 2.93e-03 | 1.27e-02 | 42 |
| GO:19016074 | Oral cavity | OSCC | alpha-amino acid biosynthetic process | 37/7305 | 68/18723 | 7.09e-03 | 2.63e-02 | 37 |
| GO:190160711 | Oral cavity | LP | alpha-amino acid biosynthetic process | 28/4623 | 68/18723 | 2.01e-03 | 1.49e-02 | 28 |
| GO:000865211 | Oral cavity | LP | cellular amino acid biosynthetic process | 30/4623 | 76/18723 | 3.07e-03 | 2.09e-02 | 30 |
| GO:000679012 | Oral cavity | LP | sulfur compound metabolic process | 106/4623 | 339/18723 | 3.36e-03 | 2.25e-02 | 106 |
| GO:00090673 | Oral cavity | LP | aspartate family amino acid biosynthetic process | 11/4623 | 21/18723 | 5.78e-03 | 3.44e-02 | 11 |
| GO:19016076 | Skin | cSCC | alpha-amino acid biosynthetic process | 30/4864 | 68/18723 | 8.91e-04 | 6.10e-03 | 30 |
| GO:00090675 | Skin | cSCC | aspartate family amino acid biosynthetic process | 12/4864 | 21/18723 | 2.40e-03 | 1.38e-02 | 12 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa002702 | Liver | HCC | Cysteine and methionine metabolism | 35/4020 | 52/8465 | 3.03e-03 | 9.94e-03 | 5.53e-03 | 35 |
| hsa002703 | Liver | HCC | Cysteine and methionine metabolism | 35/4020 | 52/8465 | 3.03e-03 | 9.94e-03 | 5.53e-03 | 35 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ENOPH1 | SNV | Missense_Mutation | novel | c.575G>T | p.Ser192Ile | p.S192I | Q9UHY7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ENOPH1 | SNV | Missense_Mutation | c.453N>G | p.Ile151Met | p.I151M | Q9UHY7 | protein_coding | deleterious(0.04) | possibly_damaging(0.721) | TCGA-BH-A18H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| ENOPH1 | insertion | Frame_Shift_Ins | novel | c.65_66insTTTAATTGTGCAGTCTACAACTTCCCCAAAT | p.Pro23LeufsTer28 | p.P23Lfs*28 | Q9UHY7 | protein_coding | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ENOPH1 | insertion | Nonsense_Mutation | novel | c.466_467insCCATCTCTACAAAAAATTAAAAAAAAAAAAAAAAGCT | p.Ser156ThrfsTer7 | p.S156Tfs*7 | Q9UHY7 | protein_coding | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD | ||
| ENOPH1 | insertion | Nonsense_Mutation | novel | c.726_727insGTATCCCATTTCCCACTCTAACTTGCTCCATTCTAGGCTGGGAGT | p.Glu242_Lys243insValSerHisPheProLeuTerLeuAlaProPheTerAlaGlySer | p.E242_K243insVSHFPL*LAPF*AGS | Q9UHY7 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ENOPH1 | SNV | Missense_Mutation | c.14C>T | p.Ser5Leu | p.S5L | Q9UHY7 | protein_coding | deleterious(0.01) | benign(0.021) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| ENOPH1 | SNV | Missense_Mutation | rs374821138 | c.106N>A | p.Glu36Lys | p.E36K | Q9UHY7 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| ENOPH1 | SNV | Missense_Mutation | novel | c.592G>T | p.Asp198Tyr | p.D198Y | Q9UHY7 | protein_coding | deleterious(0.01) | benign(0.185) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ENOPH1 | SNV | Missense_Mutation | novel | c.577T>C | p.Tyr193His | p.Y193H | Q9UHY7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ENOPH1 | SNV | Missense_Mutation | c.480N>T | p.Gln160His | p.Q160H | Q9UHY7 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |